Loading

Discovery

Preclinical

Early Stage
Clinical Development

Late Stage
Clinical Development

Regulatory Submission

Repotrectinib (ROS1/TRK)¹

TRIDENT-1: Advanced NSCLC (ROS1) and solid tumors (NTRK)
Late Stage - Clinical Development
Pediatric advanced solid tumors
Late Stage - Clinical Development
TRIDENT-2: KRAS-targeting combination
Preclinical

TPX-0022 (MET)¹

SHIELD-1: Advanced solid tumors
Early Stage - Clinical Development

SHIELD-2: EGFR combination
Preclinical

TPX-0046 (RET)²

Advanced solid tumors
Early Stage - Clinical Development

TPX-0131 (ALK)²

Advanced NSCLC
Preclinical

Discovery Programs

Multiple Oncology Targets
Discovery

¹ Partnered with Zai Lab in Greater China; Turning Point retains worldwide rights outside of Greater China. ² Turning Point retains worldwide rights.

Scroll to top